BACKGROUND AND OBJECTIVES: Rising prevalence of CKD requires active involvement of general practitioners to limit ESRD and mortality risk. However, the outcomes of patients with CKD exclusively managed by general practitioners are ill defined. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We prospectively evaluated 30,326 adult patients with nondialysis CKD stages 1-5 who had never received consultation in tertiary nephrology care recruited from 700 general practitioner offices in Italy during 2002 and 2003. CKD stages were classified as stages 1 and 2 (GFR ≥ 60 ml/min per 1.73 m(2) and either albuminuria or an International Classification of Diseases, Ninth Revision, Clinical Modification code for kidney disease), stage 3a (GFR=59-45), stage 3b (GFR=44-30), stage 4 (GFR=29-15), and stage 5 (GFR<15). Primary outcome was the risk of ESRD (dialysis or transplantation) or all-cause death. RESULTS: Overall 64% of patients were in stage 3a, and 4.5% of patients were in stages 3b-5. Patients with stages 1 and 2 were younger, were predominantly men, more frequently had diabetes, and had lower prevalence of previous cardiovascular disease than patients with stages 3a-5. Hypertension was frequent in all CKD stages (80%-94%), whereas there was a lower prevalence of dyslipidemia, albuminuria, and obesity associated with more advanced CKD. During the follow-up (median=7.2 years; interquartile range=4.7-7.7), 6592 patients died and 295 started ESRD. Compared with stages 1 and 2 (reference), mortality risk (hazard ratio, 95% confidence interval) was higher in stages 3b-5 (1.66, 1.49-1.86, 2.75, 2.41-3.13 and 2.54, 2.01-3.22, respectively) but not stage 3a (1.11, 0.99-1.23). Similarly, ESRD risk (hazard ratio, 95% confidence interval) was not higher at stage 3a (1.44, 0.79-2.64) but was greater in stages 3b-5 (11.0, 6.3-19.5, 91.2, 53.2-156.2 and, 122.8, 67.9-222.0, respectively). Among modifiable risk factors, anemia and albuminuria significantly predicted either outcome, whereas hypertension only predicted mortality. CONCLUSIONS: In patients with CKD not referred to nephrology, risks of ESRD and mortality were higher in those with CKD stages 3b-5.
BACKGROUND AND OBJECTIVES: Rising prevalence of CKD requires active involvement of general practitioners to limit ESRD and mortality risk. However, the outcomes of patients with CKD exclusively managed by general practitioners are ill defined. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We prospectively evaluated 30,326 adult patients with nondialysis CKD stages 1-5 who had never received consultation in tertiary nephrology care recruited from 700 general practitioner offices in Italy during 2002 and 2003. CKD stages were classified as stages 1 and 2 (GFR ≥ 60 ml/min per 1.73 m(2) and either albuminuria or an International Classification of Diseases, Ninth Revision, Clinical Modification code for kidney disease), stage 3a (GFR=59-45), stage 3b (GFR=44-30), stage 4 (GFR=29-15), and stage 5 (GFR<15). Primary outcome was the risk of ESRD (dialysis or transplantation) or all-cause death. RESULTS: Overall 64% of patients were in stage 3a, and 4.5% of patients were in stages 3b-5. Patients with stages 1 and 2 were younger, were predominantly men, more frequently had diabetes, and had lower prevalence of previous cardiovascular disease than patients with stages 3a-5. Hypertension was frequent in all CKD stages (80%-94%), whereas there was a lower prevalence of dyslipidemia, albuminuria, and obesity associated with more advanced CKD. During the follow-up (median=7.2 years; interquartile range=4.7-7.7), 6592 patients died and 295 started ESRD. Compared with stages 1 and 2 (reference), mortality risk (hazard ratio, 95% confidence interval) was higher in stages 3b-5 (1.66, 1.49-1.86, 2.75, 2.41-3.13 and 2.54, 2.01-3.22, respectively) but not stage 3a (1.11, 0.99-1.23). Similarly, ESRD risk (hazard ratio, 95% confidence interval) was not higher at stage 3a (1.44, 0.79-2.64) but was greater in stages 3b-5 (11.0, 6.3-19.5, 91.2, 53.2-156.2 and, 122.8, 67.9-222.0, respectively). Among modifiable risk factors, anemia and albuminuria significantly predicted either outcome, whereas hypertension only predicted mortality. CONCLUSIONS: In patients with CKD not referred to nephrology, risks of ESRD and mortality were higher in those with CKD stages 3b-5.
Authors: Tanvir Chowdhury Turin; Matthew James; Pietro Ravani; Marcello Tonelli; Braden J Manns; Robert Quinn; Min Jun; Scott Klarenbach; Brenda R Hemmelgarn Journal: J Am Soc Nephrol Date: 2013-07-05 Impact factor: 10.121
Authors: Claudio Cricelli; Giampiero Mazzaglia; Fabio Samani; Marco Marchi; Andrea Sabatini; Roberto Nardi; Giuseppe Ventriglia; Achille P Caputi Journal: J Public Health Med Date: 2003-09
Authors: Laura C Plantinga; Cristina Drenkard; Rachel E Patzer; Mitchel Klein; Michael R Kramer; Stephen Pastan; S Sam Lim; William M McClellan Journal: Arthritis Rheumatol Date: 2015-03 Impact factor: 10.995
Authors: Morgan E Grams; Wei Yang; Casey M Rebholz; Xue Wang; Anna C Porter; Lesley A Inker; Edward Horwitz; James H Sondheimer; L Lee Hamm; Jiang He; Matthew R Weir; Bernard G Jaar; Tariq Shafi; Lawrence J Appel; Chi-Yuan Hsu Journal: Am J Kidney Dis Date: 2017-03-30 Impact factor: 8.860
Authors: Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego Journal: Intern Emerg Med Date: 2018-09-25 Impact factor: 3.397
Authors: Guofen Yan; Alfred K Cheung; Tom Greene; Alison J Yu; M Norman Oliver; Wei Yu; Jennie Z Ma; Keith C Norris Journal: Clin J Am Soc Nephrol Date: 2015-10-08 Impact factor: 8.237
Authors: Pierre Delanaye; Kitty J Jager; Arend Bökenkamp; Anders Christensson; Laurence Dubourg; Bjørn Odvar Eriksen; François Gaillard; Giovanni Gambaro; Markus van der Giet; Richard J Glassock; Olafur S Indridason; Marco van Londen; Christophe Mariat; Toralf Melsom; Olivier Moranne; Gunnar Nordin; Runolfur Palsson; Hans Pottel; Andrew D Rule; Elke Schaeffner; Maarten W Taal; Christine White; Anders Grubb; Jan A J G van den Brand Journal: J Am Soc Nephrol Date: 2019-09-10 Impact factor: 10.121